Brain metastases and subtypes of breast cancer

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 803-805

  Pestalozzi, Bernhard C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR; STAT3 PROTEIN; TEMOZOLOMIDE; TRASTUZUMAB;

BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DRUG PENETRATION; EDITORIAL; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL TIME;

BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 65549124593     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp246     Document Type: Editorial

References (29)

1. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-3617.
2. Weil RJ, Palmieri DC, Bronder JL et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167: 913-920.
3. Tham YL, Sexton K, Kramer R et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696-704.
4. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-944.
5. Pestalozzi BC, Francis P, Quinaux E et al. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol 2008; 19: 1837-1841.
6. Slimane K, Andre F, Delaloge S et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004; 15: 1640-1644.
7. Dawood S, Broglio K, Esteva FJ et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20: 621-627.
8. Heitz F, PH, Traut A et al. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol 2008; 26: (Abstr 1010).
9. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
10. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
11. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
12. Schneider BP, Winer EP, Foulkes WD et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14: 8010-8018.
13. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
14. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008; 19: 1242-1248.
15. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977.
16. Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005; 16: 1772-1777.
17. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-643.
18. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 18: 2349-2351.
19. de Vries EG. Molecular imaging of breast cancer. In 11th International Conference on Primary Breast Cancer, St.Gallen, Switzerland. 2009.
20. Lin NU, Dieras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15: 1452-1459.
21. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
22. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
23. Kirsch DG, Ledezma CJ, Mathews CS et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005; 23: 2114-2116; author reply 2116-2117.
24. Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14: 1072-1077.
25. Palmieri D, Chambers AF, Felding-Habermann B et al. The biology of metastasis to a sanctuary site. Clin Cancer Res 2007; 13: 1656-1662.
26. Palmieri D, Bronder JL, Herring JM et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67: 4190-4198.
27. Gupta GP, Nguyen DX, Chiang AC et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446: 765-770.
28. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
29. Massague J. Deconstructing metastasis. In CTRC-AACR San Antonio Breast Cancer Symposium. 2008.